BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733. e9. [PMID: 22226782 DOI: 10.1053/j.gastro.2011.12.042] [Cited by in Crossref: 375] [Cited by in F6Publishing: 364] [Article Influence: 37.5] [Reference Citation Analysis]
Number Citing Articles
1 Waldmann J, Fendrich V, Reichert M, Hecker A, Bartsch DK, Padberg W, Holler JP. Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer. Journal of Surgical Research 2018;223:230-6. [DOI: 10.1016/j.jss.2017.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Fujikura K, Akita M, Abe-suzuki S, Itoh T, Zen Y. Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression. Histopathology 2017;71:591-600. [DOI: 10.1111/his.13271] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
3 Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res 2016;76:675-85. [PMID: 26676756 DOI: 10.1158/0008-5472.CAN-15-1141] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
4 Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Nagino M. Cells of origin of pancreatic neoplasms. Surg Today. 2018;48:9-17. [PMID: 28260136 DOI: 10.1007/s00595-017-1501-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
5 Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, Lin E, Brant A, Barkley T, Almario JA, Topazian M, Farrell J, Syngal S, Lee JH, Yu J, Hruban RH, Kanda M, Canto MI, Goggins M. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 2015;13:963-9.e4. [PMID: 25481712 DOI: 10.1016/j.cgh.2014.11.028] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
6 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
7 Zhou D, Yang L, Zheng L, Ge W, Li D, Zhang Y, Hu X, Gao Z, Xu J, Huang Y. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One. 2013;8:e53310. [PMID: 23301059 DOI: 10.1371/journal.pone.0053310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
8 Malik R, Luong T, Cao X, Han B, Shah N, Franco-Barraza J, Han L, Shenoy VB, Lelkes PI, Cukierman E. Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol 2019;81:50-69. [PMID: 30412725 DOI: 10.1016/j.matbio.2018.11.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Malinova A, Veghini L, Real FX, Corbo V. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol 2021;9:795251. [PMID: 34926472 DOI: 10.3389/fcell.2021.795251] [Reference Citation Analysis]
10 Ding L, Liou GY, Schmitt DM, Storz P, Zhang JS, Billadeau DD. Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia. J Pathol 2017;243:65-77. [PMID: 28639695 DOI: 10.1002/path.4928] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
11 Felsenstein M, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol. 2018;25:131-142. [PMID: 28914620 DOI: 10.1097/pap.0000000000000172] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
12 Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, di Magliano MP. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res 2014;2:423-35. [PMID: 24795355 DOI: 10.1158/2326-6066.CIR-14-0016-T] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
13 Sagami R, Yamao K, Nakahodo J, Minami R, Tsurusaki M, Murakami K, Amano Y. Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma. Cancers (Basel) 2021;13:945. [PMID: 33668239 DOI: 10.3390/cancers13050945] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
15 Donadelli M, Dando I, Dalla Pozza E, Palmieri M. Mitochondrial uncoupling protein 2 and pancreatic cancer: A new potential target therapy. World J Gastroenterol 2015; 21(11): 3232-3238 [PMID: 25805929 DOI: 10.3748/wjg.v21.i11.3232] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
16 Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA 2021;326:851-62. [PMID: 34547082 DOI: 10.1001/jama.2021.13027] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kulemann B, Rösch S, Seifert S, Timme S, Bronsert P, Seifert G, Martini V, Kuvendjiska J, Glatz T, Hussung S, Fritsch R, Becker H, Pitman MB, Hoeppner J. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Sci Rep 2017;7:4510. [PMID: 28674438 DOI: 10.1038/s41598-017-04601-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
18 Fleming AK, Storz P. Protein kinase C isoforms in the normal pancreas and in pancreatic disease. Cell Signal. 2017;40:1-9. [PMID: 28826907 DOI: 10.1016/j.cellsig.2017.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Xie VK, Maitra A. Krüppel-Like Factor 4 Promotes Pancreatic Acinar-to-Ductal Metaplasia and Tumor Initiation. Pancreas 2017;46:139-42. [DOI: 10.1097/mpa.0000000000000773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
20 Suenaga M, Dudley B, Karloski E, Borges M, Irene Canto M, Brand RE, Goggins M. The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations. Pancreas 2018;47:35-9. [PMID: 29200129 DOI: 10.1097/MPA.0000000000000956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Genrich G, Kruppa M, Lenk L, Helm O, Broich A, Freitag-Wolf S, Röcken C, Sipos B, Schäfer H, Sebens S. The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1. BMC Cancer 2016;16:155. [PMID: 26915435 DOI: 10.1186/s12885-016-2191-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
22 Mortoglou M, Tabin ZK, Arisan ED, Kocher HM, Uysal-Onganer P. Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. Transl Oncol 2021;14:101090. [PMID: 33831655 DOI: 10.1016/j.tranon.2021.101090] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Reference Citation Analysis]
24 Freeny PC, Saunders MD. Moving beyond morphology: new insights into the characterization and management of cystic pancreatic lesions. Radiology. 2014;272:345-363. [PMID: 25058133 DOI: 10.1148/radiol.14131126] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
25 Matsumoto K, Kato H, Nouso K, Ako S, Kinugasa H, Horiguchi S, Saragai Y, Takada S, Yabe S, Muro S, Uchida D, Tomoda T, Okada H. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Dig Dis Sci 2020;65:2907-13. [PMID: 31897893 DOI: 10.1007/s10620-019-06006-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Gao C, Chen G, Zhang DH, Zhang J, Kuan SF, Hu W, Esni F, Gao X, Guan JL, Chu E, Hu J. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654. Cell Mol Gastroenterol Hepatol 2019;8:561-78. [PMID: 31330317 DOI: 10.1016/j.jcmgh.2019.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Halvey PJ, Ferrone CR, Liebler DC. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res 2012;11:3908-13. [PMID: 22671702 DOI: 10.1021/pr300161j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
28 Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. J Pancreat Cancer 2018;4:81-7. [PMID: 30788462 DOI: 10.1089/pancan.2018.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Sano M, Driscoll DR, DeJesus-Monge WE, Quattrochi B, Appleman VA, Ou J, Zhu LJ, Yoshida N, Yamazaki S, Takayama T, Sugitani M, Nemoto N, Klimstra DS, Lewis BC. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. Neoplasia 2016;18:785-94. [PMID: 27889647 DOI: 10.1016/j.neo.2016.11.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
30 Mills LD, Zhang Y, Marler RJ, Herreros-Villanueva M, Zhang L, Almada LL, Couch F, Wetmore C, Pasca di Magliano M, Fernandez-Zapico ME. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem 2013;288:11786-94. [PMID: 23482563 DOI: 10.1074/jbc.M112.438846] [Cited by in Crossref: 78] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
31 Schmahl MJ, Regan DP, Rivers AC, Joesten WC, Kennedy MA. NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer. PLoS One 2018;13:e0200658. [PMID: 30016349 DOI: 10.1371/journal.pone.0200658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
32 Wu Y, Zeng H, Yu Q, Huang H, Fervers B, Chen ZS, Lu L. A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. Cancers (Basel) 2021;13:2565. [PMID: 34073722 DOI: 10.3390/cancers13112565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452 [PMID: 27672267 DOI: 10.3748/wjg.v22.i33.7440] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
34 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
35 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
36 Notta F, Hahn SA, Real FX. A genetic roadmap of pancreatic cancer: still evolving. Gut. 2017;66:2170-2178. [PMID: 28993418 DOI: 10.1136/gutjnl-2016-313317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
37 Pitarresi JR, Liu X, Sharma SM, Cuitiño MC, Kladney RD, Mace TA, Donohue S, Nayak SG, Qu C, Lee J, Woelke SA, Trela S, LaPak K, Yu L, McElroy J, Rosol TJ, Shakya R, Ludwig T, Lesinski GB, Fernandez SA, Konieczny SF, Leone G, Wu J, Ostrowski MC. Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. Neoplasia 2016;18:541-52. [PMID: 27659014 DOI: 10.1016/j.neo.2016.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
38 Asahina K. Induction of Cell Death in Pancreatic Tumors by Zinc and Its Fluorescence Chelator TSQ. Biol Trace Elem Res 2021. [PMID: 34100198 DOI: 10.1007/s12011-021-02770-7] [Reference Citation Analysis]
39 Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends Cancer 2017;3:336-46. [PMID: 28718411 DOI: 10.1016/j.trecan.2017.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
40 Bansod S, Dodhiawala PB, Lim KH. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers (Basel) 2021;13:5481. [PMID: 34771644 DOI: 10.3390/cancers13215481] [Reference Citation Analysis]
41 Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-rayes BF. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Letters 2013;341:195-203. [DOI: 10.1016/j.canlet.2013.08.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 6.8] [Reference Citation Analysis]
42 Wood LD, Hruban RH. Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med 2015;49:13-22. [PMID: 25812653 DOI: 10.4132/jptm.2014.12.26] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
43 Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci. 2016;144:241-275. [PMID: 27865459 DOI: 10.1016/bs.pmbts.2016.09.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
44 Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 2012;18:4257-4265. [PMID: 22896692 DOI: 10.1158/1078-0432.ccr-12-0315] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
45 Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol. 2015;42:28-39. [PMID: 25726050 DOI: 10.1053/j.seminoncol.2014.12.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
46 Garcia MN, Grasso D, Lopez-Millan MB, Hamidi T, Loncle C, Tomasini R, Lomberk G, Porteu F, Urrutia R, Iovanna JL. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. J Clin Invest 2014;124:4709-22. [PMID: 25250570 DOI: 10.1172/JCI76037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
47 von Burstin J, Diersch S, Schneider G, Reichert M, Rustgi AK, Schmid RM. Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method. Mol Cancer Res 2015;13:863-9. [PMID: 25724428 DOI: 10.1158/1541-7786.MCR-14-0709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73-85. [PMID: 26830752 DOI: 10.1016/s0140-6736(16)00141-0] [Cited by in Crossref: 995] [Cited by in F6Publishing: 643] [Article Influence: 165.8] [Reference Citation Analysis]
49 Group Young Researchers In Inflammatory Carcinogenesis, Wandmacher AM, Mehdorn AS, Sebens S. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers (Basel) 2021;13:4932. [PMID: 34638420 DOI: 10.3390/cancers13194932] [Reference Citation Analysis]
50 Omori Y, Ono Y, Tanino M, Karasaki H, Yamaguchi H, Furukawa T, Enomoto K, Ueda J, Sumi A, Katayama J, Muraki M, Taniue K, Takahashi K, Ambo Y, Shinohara T, Nishihara H, Sasajima J, Maguchi H, Mizukami Y, Okumura T, Tanaka S. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology 2019; 156: 647-661. e2. [PMID: 30342036 DOI: 10.1053/j.gastro.2018.10.029] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 14.5] [Reference Citation Analysis]
51 Hruban RH, Klimstra DS. Adenocarcinoma of the pancreas. Semin Diagn Pathol 2014;31:443-51. [PMID: 25441308 DOI: 10.1053/j.semdp.2014.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
52 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
53 Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 2014;5:6512-25. [PMID: 25156567 DOI: 10.18632/oncotarget.2270] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 17.9] [Reference Citation Analysis]
54 Feuerecker B, Biechl P, Veltkamp C, Saur D, Eisenreich W. Metabolic Response of Pancreatic Carcinoma Cells under Treatment with Dichloroacetate. Metabolites 2021;11:350. [PMID: 34070873 DOI: 10.3390/metabo11060350] [Reference Citation Analysis]
55 Tan SJO, Floriano JF, Nicastro L, Emanueli C, Catapano F. Novel Applications of Mesenchymal Stem Cell-derived Exosomes for Myocardial Infarction Therapeutics. Biomolecules 2020;10:E707. [PMID: 32370160 DOI: 10.3390/biom10050707] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
56 Macgregor-Das A, Yu J, Tamura K, Abe T, Suenaga M, Shindo K, Borges M, Koi C, Kohi S, Sadakari Y, Dal Molin M, Almario JA, Ford M, Chuidian M, Burkhart R, He J, Hruban RH, Eshleman JR, Klein AP, Wolfgang CL, Canto MI, Goggins M. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. J Mol Diagn 2020;22:748-56. [PMID: 32205290 DOI: 10.1016/j.jmoldx.2020.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Bell K, McKenzie HA, Shaw DC. Haemoglobin, serum albumin and transferrin variants of Bali (Banteng) cattle, Bos (Bibos) javanicus. Comp Biochem Physiol B. 1990;95:825-832. [PMID: 2344736 DOI: 10.1002/ijc.28134] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 2.3] [Reference Citation Analysis]
58 Miller MS, Allen P, Brentnall TA, Goggins M, Hruban RH, Petersen GM, Rao CV, Whitcomb DC, Brand RE, Chari ST, Klein AP, Lubman DM, Rhim AD, Simeone DM, Wolpin BM, Umar A, Srivastava S, Steele VE, Rinaudo JA. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Pancreas. 2016;45:1080-1091. [PMID: 27518363 DOI: 10.1097/mpa.0000000000000705] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
59 Kuboki Y, Fischer CG, Beleva Guthrie V, Huang W, Yu J, Chianchiano P, Hosoda W, Zhang H, Zheng L, Shao X, Thompson ED, Waters K, Poling J, He J, Weiss MJ, Wolfgang CL, Goggins MG, Hruban RH, Roberts NJ, Karchin R, Wood LD. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol 2019;247:347-56. [PMID: 30430578 DOI: 10.1002/path.5194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
60 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 8.4] [Reference Citation Analysis]
61 Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, Li X, Zhang W, Zhou HH, Liu ZQ. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget 2017;8:21281-9. [PMID: 28177904 DOI: 10.18632/oncotarget.15068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
62 Seymour PA. Sox9: a master regulator of the pancreatic program. Rev Diabet Stud 2014;11:51-83. [PMID: 25148367 DOI: 10.1900/RDS.2014.11.51] [Cited by in Crossref: 52] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
63 Jun I, Park HS, Piao H, Han JW, An MJ, Yun BG, Zhang X, Cha YH, Shin YK, Yook JI, Jung J, Gee HY, Park JS, Yoon DS, Jeung HC, Lee MG. ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Br J Cancer 2017;117:1798-809. [PMID: 29024940 DOI: 10.1038/bjc.2017.355] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
64 Schröter P, Hartmann L, Osen W, Baumann D, Offringa R, Eisel D, Debus J, Eichmüller SB, Rieken S. Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. Sci Rep 2020;10:686. [PMID: 31959787 DOI: 10.1038/s41598-020-57456-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol 2021:S0748-7983(21)00947-1. [PMID: 34876329 DOI: 10.1016/j.ejso.2021.11.138] [Reference Citation Analysis]
66 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
67 Jeannot P, Callot C, Baer R, Duquesnes N, Guerra C, Guillermet-Guibert J, Bachs O, Besson A. Loss of p27Kip¹ promotes metaplasia in the pancreas via the regulation of Sox9 expression. Oncotarget 2015;6:35880-92. [PMID: 26416424 DOI: 10.18632/oncotarget.5770] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
68 Silke J, O'Reilly LA. NF-κB and Pancreatic Cancer; Chapter and Verse. Cancers (Basel) 2021;13:4510. [PMID: 34572737 DOI: 10.3390/cancers13184510] [Reference Citation Analysis]
69 Veite-Schmahl MJ, Rivers AC, Regan DP, Kennedy MA. The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+;LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer. PLoS One 2017;12:e0187552. [PMID: 29121082 DOI: 10.1371/journal.pone.0187552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
70 Lu J, Roy B, Anderson M, Leggett CL, Levy MJ, Pogue B, Hasan T, Wang KK. Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. J Biomed Opt 2019;24:1-11. [PMID: 31741351 DOI: 10.1117/1.JBO.24.11.118001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
71 Dey S, Kwon JJ, Liu S, Hodge GA, Taleb S, Zimmers TA, Wan J, Kota J. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. Mol Cancer Res 2020;18:311-23. [PMID: 31662451 DOI: 10.1158/1541-7786.MCR-19-0594] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
72 Chen SJ, Chen YT, Zeng LJ, Zhang QB, Lian GD, Li JJ, Yang KG, Huang CM, Li YQ, Chu ZH, Huang KH. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro. Tumour Biol 2016;37:11299-309. [PMID: 26951514 DOI: 10.1007/s13277-016-4840-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
73 Bhutani MS, Thosani N, Suzuki R, Guha S. Pancreatic cancer screening: what we do and do not know. Clin Gastroenterol Hepatol 2013;11:731-3. [PMID: 23403010 DOI: 10.1016/j.cgh.2013.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
74 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Garcia PE, Scales MK, Allen BL, Pasca di Magliano M. Pancreatic Fibroblast Heterogeneity: From Development to Cancer. Cells 2020;9:E2464. [PMID: 33198201 DOI: 10.3390/cells9112464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Okada T, Mizukami Y, Ono Y, Sato H, Hayashi A, Kawabata H, Koizumi K, Masuda S, Teshima S, Takahashi K, Katanuma A, Omori Y, Iwano H, Yamada M, Yokochi T, Asahara S, Kawakubo K, Kuwatani M, Sakamoto N, Enomoto K, Goto T, Sasajima J, Fujiya M, Ueda J, Matsumoto S, Taniue K, Sugitani A, Karasaki H, Okumura T. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. J Gastroenterol. 2020;55:1183-1193. [PMID: 32939577 DOI: 10.1007/s00535-020-01724-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Schofield HK, Zeller J, Espinoza C, Halbrook CJ, Del Vecchio A, Magnuson B, Fabo T, Daylan AEC, Kovalenko I, Lee HJ, Yan W, Feng Y, Karim SA, Kremer DM, Kumar-Sinha C, Lyssiotis CA, Ljungman M, Morton JP, Galbán S, Fearon ER, Pasca di Magliano M. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 2018;3:97422. [PMID: 29367463 DOI: 10.1172/jci.insight.97422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
78 Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, Kamel I, Lennon AM, Borges M, Young A. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2013;62:1024-1033. [PMID: 22859495 DOI: 10.1136/gutjnl-2012-302823] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 11.9] [Reference Citation Analysis]
79 di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144:1220-1229. [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071] [Cited by in Crossref: 230] [Cited by in F6Publishing: 218] [Article Influence: 25.6] [Reference Citation Analysis]
80 Diaconescu S, Gîlcă-Blanariu GE, Poamaneagra S, Marginean O, Paduraru G, Stefanescu G. Could the burden of pancreatic cancer originate in childhood? World J Gastroenterol 2021; 27(32): 5322-5340 [PMID: 34539135 DOI: 10.3748/wjg.v27.i32.5322] [Reference Citation Analysis]
81 Chang XY, Wu Y, Li Y, Wang J, Chen J. Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS. Mol Med Rep 2018;17:8061-8. [PMID: 29658583 DOI: 10.3892/mmr.2018.8875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
82 Kopp JL, Sander M. New insights into the cell lineage of pancreatic ductal adenocarcinoma: evidence for tumor stem cells in premalignant lesions? Gastroenterology 2014;146:24-6. [PMID: 24275238 DOI: 10.1053/j.gastro.2013.11.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
83 Nagrath S, Jack RM, Sahai V, Simeone DM. Opportunities and Challenges for Pancreatic Circulating Tumor Cells. Gastroenterology. 2016;151:412-426. [PMID: 27339829 DOI: 10.1053/j.gastro.2016.05.052] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
84 Zhang Y, Yan W, Mathew E, Kane KT, Brannon A 3rd, Adoumie M, Vinta A, Crawford HC, Pasca di Magliano M. Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. Elife 2017;6:e27388. [PMID: 28980940 DOI: 10.7554/eLife.27388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
85 Li C, Peng Z, Wang Y, Lam G, Nissen N, Tang J, Yuan X, Lewis M, Greene MI, Pandol SJ, Wang Q. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Am J Physiol Gastrointest Liver Physiol 2021;320:G380-95. [PMID: 33501895 DOI: 10.1152/ajpgi.00185.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Bijlsma MF, van Laarhoven HW. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 2015;34:97-114. [PMID: 25566685 DOI: 10.1007/s10555-014-9541-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
87 Zaccari P, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World J Gastroenterol 2019; 25(31): 4343-4359 [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
88 Li C, Morvaridi S, Lam G, Chheda C, Kamata Y, Katsumata M, Edderkaoui M, Yuan X, Nissen N, Pandol SJ, Wang Q. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Front Physiol. 2019;10:147. [PMID: 30863319 DOI: 10.3389/fphys.2019.00147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
89 Omura N, Mizuma M, MacGregor A, Hong SM, Ayars M, Almario JA, Borges M, Kanda M, Li A, Vincent A, Maitra A, Goggins M. Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget 2016;7:34977-87. [PMID: 27144336 DOI: 10.18632/oncotarget.9009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
90 Rozengurt E, Eibl G. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. World J Gastroenterol 2019; 25(15): 1797-1816 [PMID: 31057295 DOI: 10.3748/wjg.v25.i15.1797] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
91 Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) 2016;8:E45. [PMID: 27096871 DOI: 10.3390/cancers8040045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 16.7] [Reference Citation Analysis]
92 Hata T, Dal Molin M, McGregor-Das A, Song TJ, Wolfgang C, Eshleman JR, Hruban RH, Goggins M. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. J Mol Diagn 2018;20:46-55. [PMID: 29229290 DOI: 10.1016/j.jmoldx.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
93 Wang W, Friedland SC, Guo B, O'Dell MR, Alexander WB, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Myers JR, Ashton JM, Dunne RF, Steiner LA, Hezel AF. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas. Gut 2019;68:1245-58. [PMID: 30228219 DOI: 10.1136/gutjnl-2017-315541] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
94 Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res. 2012;10:1228-1239. [PMID: 22871572 DOI: 10.1158/1541-7786.mcr-12-0340-t] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
95 Matsubara A, Ogawa R, Suzuki H, Oda I, Taniguchi H, Kanai Y, Kushima R, Sekine S. Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum. Br J Cancer 2015;112:1398-404. [PMID: 25867268 DOI: 10.1038/bjc.2015.104] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
96 Morita K, Mito K, Niki T, Fukushima N. Is an atypical flat lesion (AFL) a precursor lesion of the pancreatic ductal adenocarcinoma in human? Pathol Int 2018. [PMID: 29664180 DOI: 10.1111/pin.12670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
97 Yoon S, Rossi JJ. Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA. Adv Exp Med Biol 2017;983:173-88. [PMID: 28639199 DOI: 10.1007/978-981-10-4310-9_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
98 Drosten M, Guerra C, Barbacid M. Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harb Perspect Med 2018;8:a031542. [PMID: 28778964 DOI: 10.1101/cshperspect.a031542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
99 Martinez-useros J, Li W, Georgiev-hristov T, Fernandez-aceñero MJ, Borrero-palacios A, Perez N, Celdran A, Garcia-foncillas J. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathol Oncol Res 2019;25:269-78. [DOI: 10.1007/s12253-017-0341-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Pinho DF, Subramaniam RM. PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. PET Clinics 2017;12:407-21. [DOI: 10.1016/j.cpet.2017.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
101 Li S, Counter CM. Signaling levels mold the RAS mutation tropism of urethane. Elife 2021;10:e67172. [PMID: 33998997 DOI: 10.7554/eLife.67172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Metildi CA, Kaushal S, Hoffman RM, Bouvet M. In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status. J Surg Res 2013;184:290-8. [PMID: 23590868 DOI: 10.1016/j.jss.2013.03.049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
103 Xia L, Dai L, Yang Q. Transmissible gastroenteritis virus infection decreases arginine uptake by downregulating CAT-1 expression. Vet Res 2018;49:95. [PMID: 30236161 DOI: 10.1186/s13567-018-0591-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 Matsuda Y, Furukawa T, Yachida S, Nishimura M, Seki A, Nonaka K, Aida J, Takubo K, Ishiwata T, Kimura W, Arai T, Mino-kenudson M. The Prevalence and Clinicopathological Characteristics of High-Grade Pancreatic Intraepithelial Neoplasia: Autopsy Study Evaluating the Entire Pancreatic Parenchyma. Pancreas 2017;46:658-64. [DOI: 10.1097/mpa.0000000000000786] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
105 Matsuda Y, Tanaka M, Sawabe M, Mori S, Muramatsu M, Mieno MN, Furukawa T, Arai T. Relationship between pancreatic intraepithelial neoplasias, pancreatic ductal adenocarcinomas, and single nucleotide polymorphisms in autopsied elderly patients. Genes Chromosomes Cancer 2018;57:12-8. [DOI: 10.1002/gcc.22479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Kim MJ, Kim MS, Kim SJ, An S, Park J, Park H, Lee JH, Song KB, Hwang DW, Chang S, Kim KP, Jeong SY, Kim SC, Hong SM. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Cancer Cell Int 2017;17:47. [PMID: 28435405 DOI: 10.1186/s12935-017-0416-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
107 Nattress CB, Halldén G. Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett 2018;434:56-69. [PMID: 29981812 DOI: 10.1016/j.canlet.2018.07.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
108 Singhi AD, Wood LD. Early detection of pancreatic cancer using DNA-based molecular approaches. Nat Rev Gastroenterol Hepatol 2021;18:457-68. [PMID: 34099908 DOI: 10.1038/s41575-021-00470-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
109 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
110 Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, Kato Y, Klimstra DS, Klöppel G, Krasinskas A, Longnecker DS, Matthaei H, Offerhaus GJ, Shimizu M, Takaori K, Terris B, Yachida S, Esposito I, Furukawa T; Baltimore Consensus Meeting. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 2015;39:1730-41. [PMID: 26559377 DOI: 10.1097/PAS.0000000000000533] [Cited by in Crossref: 367] [Cited by in F6Publishing: 159] [Article Influence: 61.2] [Reference Citation Analysis]
111 Miyazono K, Katsuno Y, Koinuma D, Ehata S, Morikawa M. Intracellular and extracellular TGF-β signaling in cancer: some recent topics. Front Med 2018;12:387-411. [PMID: 30043220 DOI: 10.1007/s11684-018-0646-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
112 Levink I, Bruno MJ, Cahen DL. Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives. Curr Treat Options Gastroenterol. 2018;16:316-332. [PMID: 30196428 DOI: 10.1007/s11938-018-0190-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
113 Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015;6:15788-801. [PMID: 26158861 DOI: 10.18632/oncotarget.3819] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
114 Teper Y, Eibl G. Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer. Cancers (Basel) 2020;12:E1946. [PMID: 32709161 DOI: 10.3390/cancers12071946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Axilbund JE, Wiley EA. Genetic testing by cancer site: pancreas. Cancer J 2012;18:350-4. [PMID: 22846737 DOI: 10.1097/PPO.0b013e3182624694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
116 Utomo WK, Narayanan V, Biermann K, van Eijck CH, Bruno MJ, Peppelenbosch MP, Braat H. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett 2014;346:309-17. [PMID: 24467966 DOI: 10.1016/j.canlet.2014.01.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
117 Wei D, Wang L, Yan Y, Jia Z, Gagea M, Li Z, Zuo X, Kong X, Huang S, Xie K. KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis. Cancer Cell 2016;29:324-38. [PMID: 26977883 DOI: 10.1016/j.ccell.2016.02.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 12.8] [Reference Citation Analysis]
118 Ohtsuki Y, Watanabe R, Kimura M, Nomura K, Maeda T, Kito K, Takeji M, Lee GH, Furihata M. Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia. Med Mol Morphol 2015;48:85-91. [PMID: 24908068 DOI: 10.1007/s00795-014-0080-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Yu Y, Yang G, Huang H, Fu Z, Cao Z, Zheng L, You L, Zhang T. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. J Exp Clin Cancer Res 2021;40:8. [PMID: 33402215 DOI: 10.1186/s13046-020-01787-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
120 Sato H, Liss AS, Mizukami Y. Large-duct pattern invasive adenocarcinoma of the pancreas–a variant mimicking pancreatic cystic neoplasms: A minireview. World J Gastroenterol 2021; 27(23): 3262-3278 [PMID: 34163110 DOI: 10.3748/wjg.v27.i23.3262] [Reference Citation Analysis]
121 Tripathi K, Garg M. Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer. J Cell Commun Signal. 2018;12:513-527. [PMID: 29330773 DOI: 10.1007/s12079-017-0441-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
122 Peng JF, Zhuang YY, Huang FT, Zhang SN. Noncoding RNAs and pancreatic cancer. World J Gastroenterol 2016; 22(2): 801-814 [PMID: 26811626 DOI: 10.3748/wjg.v22.i2.801] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
123 Quinn SN, Graves SH, Dains-McGahee C, Friedman EM, Hassan H, Witkowski P, Sabbatini ME. Adenylyl cyclase 3/adenylyl cyclase-associated protein 1 (CAP1) complex mediates the anti-migratory effect of forskolin in pancreatic cancer cells. Mol Carcinog 2017;56:1344-60. [PMID: 27891679 DOI: 10.1002/mc.22598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
124 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
125 Tan Z, Yi X, Carruthers NJ, Stemmer PM, Lubman DM. Single Amino Acid Variant Discovery in Small Numbers of Cells. J Proteome Res 2019;18:417-25. [PMID: 30404448 DOI: 10.1021/acs.jproteome.8b00694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
126 Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res 2015;21:1549-57. [PMID: 25623216 DOI: 10.1158/1078-0432.CCR-14-1186] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
127 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
128 Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell 2019; 176: 491-504. e21. [PMID: 30612740 DOI: 10.1016/j.cell.2018.11.038] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
129 Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol 2021; 27(21): 2710-2726 [PMID: 34135550 DOI: 10.3748/wjg.v27.i21.2710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Vincent A, Hong SM, Hu C, Omura N, Young A, Kim H, Yu J, Knight S, Ayars M, Griffith M, Van Seuningen I, Maitra A, Goggins M. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget 2014;5:2575-87. [PMID: 24810906 DOI: 10.18632/oncotarget.1842] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
131 Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, Fishman EK, Kamel I, Weiss MJ, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH. The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia? Cancer Res 2014;74:3381-9. [DOI: 10.1158/0008-5472.can-14-0734] [Cited by in Crossref: 144] [Cited by in F6Publishing: 80] [Article Influence: 18.0] [Reference Citation Analysis]
132 Zhu Z, Liu T, Han F, Zhan SD, Wang CY. Mutations in the p16 gene in DMBA-induced pancreatic intraepithelial neoplasia and pancreatic cancer in rats. Hepatobiliary Pancreat Dis Int. 2015;14:208-214. [PMID: 25865695 DOI: 10.1016/S1499-3872(15)60331-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, Hruban RH, Netto GJ, Stoler MH, Taube JM, Vang R, Westra WH, Montgomery EA. Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. CA Cancer J Clin 2016;66:408-36. [PMID: 27270763 DOI: 10.3322/caac.21350] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
134 Kato H, Tateishi K, Fujiwara H, Ijichi H, Yamamoto K, Nakatsuka T, Kakiuchi M, Sano M, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Otsuka M, Hirata Y, Tachibana M, Shinkai Y, Koike K. Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. Cancer Genomics Proteomics 2020;17:695-705. [PMID: 33099471 DOI: 10.21873/cgp.20224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis 2013;34:858-63. [PMID: 23302291 DOI: 10.1093/carcin/bgt002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
136 Quan M, Wang P, Cui J, Gao Y, Xie K. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer 2013;12:159. [PMID: 24325450 DOI: 10.1186/1476-4598-12-159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
137 Suenaga M, Sadakari Y, Almario JA, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Using an endoscopic distal cap to collect pancreatic fluid from the ampulla (with video). Gastrointest Endosc 2017;86:1152-1156.e2. [PMID: 28259593 DOI: 10.1016/j.gie.2017.02.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
138 Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene. 2014;33:2454-2463. [PMID: 23752186 DOI: 10.1038/onc.2013.204] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
139 Matthaei H, Wu J, Dal Molin M, Shi C, Perner S, Kristiansen G, Lingohr P, Kalff JC, Wolfgang CL, Kinzler KW, Vogelstein B, Maitra A, Hruban RH. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol 2014;38:360-3. [PMID: 24525507 DOI: 10.1097/PAS.0000000000000117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
140 Takano S, Fukasawa M, Maekawa S, Kadokura M, Miura M, Shindo H, Takahashi E, Sato T, Enomoto N. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One 2014;9:e98718. [PMID: 24897499 DOI: 10.1371/journal.pone.0098718] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
141 Tsesmelis M, Tiwary K, Steiger K, Sperb N, Gerstenlauer M, Manfras U, Maier HJ, Hermann PC, Chan LK, Wirth T. Deletion of NEMO Inhibits EMT and Reduces Metastasis in KPC Mice. Cancers (Basel) 2021;13:4541. [PMID: 34572768 DOI: 10.3390/cancers13184541] [Reference Citation Analysis]
142 Minciacchi VR, Zijlstra A, Rubin MA, Di Vizio D. Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis 2017;20:251-8. [PMID: 28374743 DOI: 10.1038/pcan.2017.7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
143 An S, Kim MJ, Kim SJ, Sung YN, Kim YW, Song KB, Hwang DW, Kim SC, Hruban RH, Hong SM. Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas. Histopathology 2019;75:559-67. [PMID: 31077597 DOI: 10.1111/his.13897] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
144 Saeki K, Miyasaka Y, Ohishi Y, Yamamoto T, Matsuda R, Mochidome N, Mori Y, Nakata K, Ohtsuka T, Ishigami K, Minoda Y, Koga Y, Oda Y, Nakamura M. Intrapancreatic recurrence of intraductal tubulopapillary neoplasm (ITPN) 16 years after the initial surgery for noninvasive ITPN: a case report. Surg Case Rep 2018;4:96. [PMID: 30116990 DOI: 10.1186/s40792-018-0497-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Hanada K, Okazaki A, Hirano N, Izumi Y, Minami T, Ikemoto J, Kanemitsu K, Hino F. Effective screening for early diagnosis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2015;29:929-39. [PMID: 26651254 DOI: 10.1016/j.bpg.2015.09.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
146 Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021;40:819-35. [PMID: 34499267 DOI: 10.1007/s10555-021-09990-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 To YH, Lee B, Wong HL, Gibbs P, Tie J. Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. Visc Med 2020;36:388-96. [PMID: 33178736 DOI: 10.1159/000509657] [Reference Citation Analysis]
148 Hoskins JW, Jia J, Flandez M, Parikh H, Xiao W, Collins I, Emmanuel MA, Ibrahim A, Powell J, Zhang L, Malats N, Bamlet WR, Petersen GM, Real FX, Amundadottir LT. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. Carcinogenesis 2014;35:2670-8. [PMID: 25233928 DOI: 10.1093/carcin/bgu193] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
149 Hwang KL, Goessling W. Baiting for Cancer: Using the Zebrafish as a Model in Liver and Pancreatic Cancer. In: Langenau DM, editor. Cancer and Zebrafish. Cham: Springer International Publishing; 2016. pp. 391-410. [DOI: 10.1007/978-3-319-30654-4_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
150 Chien W, Sudo M, Ding LW, Sun QY, Wuensche P, Lee KL, Hattori N, Garg M, Xu L, Zheng Y, Gery S, Wongphayak S, Yang H, Baloglu E, Shacham S, Kauffman M, Mori S, Koeffler HP. Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. J Cancer 2018;9:4762-73. [PMID: 30588262 DOI: 10.7150/jca.25138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
151 Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 2021;373:eabj0486. [PMID: 34529467 DOI: 10.1126/science.abj0486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
152 Hosoda W, Wood LD. Molecular Genetics of Pancreatic Neoplasms. Surg Pathol Clin 2016;9:685-703. [PMID: 27926367 DOI: 10.1016/j.path.2016.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
153 Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19:3600-3610. [PMID: 23697990 DOI: 10.1158/1078-0432.ccr-12-3092] [Cited by in Crossref: 176] [Cited by in F6Publishing: 123] [Article Influence: 19.6] [Reference Citation Analysis]
154 Ferreira RMM, Sancho R, Messal HA, Nye E, Spencer-Dene B, Stone RK, Stamp G, Rosewell I, Quaglia A, Behrens A. Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression. Cell Rep 2017;21:966-78. [PMID: 29069604 DOI: 10.1016/j.celrep.2017.09.093] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
155 Fischer CG, Wood LD. From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions. J Pathol 2018;246:395-404. [PMID: 30105857 DOI: 10.1002/path.5154] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
156 Hayashi H, Uemura N, Zhao L, Matsumura K, Sato H, Shiraishi Y, Baba H. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:700315. [PMID: 34395269 DOI: 10.3389/fonc.2021.700315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Zhang Y, Zhu L, Wang X. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. Genes (Basel) 2020;11:E155. [PMID: 32024063 DOI: 10.3390/genes11020155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Satyananda V, Gupta R, Hari DM, Yeh J, Chen KT. Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed? Gastroenterol Res Pract 2019;2019:7690528. [PMID: 30863442 DOI: 10.1155/2019/7690528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
159 Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN, Berthezène P, Rubis M, Secq V, Garcia S, Moutardier V, Lombardo D, Iovanna JL, Tomasini R, Guillaumond F, Vander Heiden MG, Vasseur S. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun 2017;8:16031. [PMID: 28685754 DOI: 10.1038/ncomms16031] [Cited by in Crossref: 136] [Cited by in F6Publishing: 124] [Article Influence: 27.2] [Reference Citation Analysis]
160 Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di Magliano MP. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013;73:6359-74. [PMID: 24097820 DOI: 10.1158/0008-5472.CAN-13-1558-T] [Cited by in Crossref: 133] [Cited by in F6Publishing: 90] [Article Influence: 14.8] [Reference Citation Analysis]
161 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
162 Collins MA, Yan W, Sebolt-Leopold JS, Pasca di Magliano M. MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology. 2014;146:822-834.e7. [PMID: 24315826 DOI: 10.1053/j.gastro.2013.11.052] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
163 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
164 Sasaki M, Nitta T, Sato Y, Nakanuma Y. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. Am J Clin Pathol 2016;145:815-25. [DOI: 10.1093/ajcp/aqw071] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
165 Wood LD. Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy. Mol Diagn Ther 2013;17:287-97. [PMID: 23757204 DOI: 10.1007/s40291-013-0043-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
166 Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013; 11: 719-30. e5. [PMID: 23200980 DOI: 10.1016/j.cgh.2012.11.016] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 10.6] [Reference Citation Analysis]
167 Ideno N, Mori Y, Nakamura M, Ohtsuka T. Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples. Diagnostics (Basel). 2020;10. [PMID: 33291257 DOI: 10.3390/diagnostics10121056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
168 Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, Melisi D. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget 2015;6:13822-34. [PMID: 25360865 DOI: 10.18632/oncotarget.2635] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
169 Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol 2015; 21(34): 9838-9852 [PMID: 26379391 DOI: 10.3748/wjg.v21.i34.9838] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
170 Salaymeh Y, Farago M, Sebban S, Shalom B, Pikarsky E, Katzav S. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice. Life Sci Alliance 2020;3:e202000661. [PMID: 32277014 DOI: 10.26508/lsa.202000661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
172 Schäfer H, Traulsen A, Sebens S. Killer on the road?-cells from pancreatic preneoplastic lesions disseminate through pancreatic ducts on their way to cancer. Hepatobiliary Surg Nutr 2019;8:392-4. [PMID: 31489311 DOI: 10.21037/hbsn.2019.06.03] [Reference Citation Analysis]
173 Sasaki M, Matsubara T, Nitta T, Sato Y, Nakanuma Y. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One. 2013;8:e81706. [PMID: 24312577 DOI: 10.1371/journal.pone.0081706] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
174 Sadakari Y, Kanda M, Maitani K, Borges M, Canto MI, Goggins M. Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clin Transl Gastroenterol 2014;5:e62. [PMID: 25393586 DOI: 10.1038/ctg.2014.14] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
175 Schimmack S, Kneller S, Dadabaeva N, Bergmann F, Taylor A, Hackert T, Werner J, Strobel O. Epithelial to Stromal Re-Distribution of Primary Cilia during Pancreatic Carcinogenesis. PLoS One 2016;11:e0164231. [PMID: 27783689 DOI: 10.1371/journal.pone.0164231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
176 Gao HL, Wang WQ, Yu XJ, Liu L. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Exp Hematol Oncol 2020;9:28. [PMID: 33101770 DOI: 10.1186/s40164-020-00184-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
177 Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, Lee K, Wei J, Liu B. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumor Biol 2014;35:2047-51. [DOI: 10.1007/s13277-013-1271-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
178 Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Enomoto A, Nagino M. Trefoil factor 1 inhibits epithelial-mesenchymal transition of pancreatic intraepithelial neoplasm. J Clin Invest 2018;128:3619-29. [PMID: 29809170 DOI: 10.1172/JCI97755] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
179 Visani M, de Biase D, Baccarini P, Fabbri C, Polifemo AM, Zanini N, Pession A, Tallini G. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Int J Surg Pathol. 2013;21:546-552. [PMID: 23426962 DOI: 10.1177/1066896912475073] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
180 Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci 2017;18:E779. [PMID: 28383487 DOI: 10.3390/ijms18040779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
181 Fujii A, Masuda T, Iwata M, Tobo T, Wakiyama H, Koike K, Kosai K, Nakano T, Kuramitsu S, Kitagawa A, Sato K, Kouyama Y, Shimizu D, Matsumoto Y, Utsunomiya T, Ohtsuka T, Yamanishi Y, Nakamura M, Mimori K. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. Cancer Sci 2021;112:1655-68. [PMID: 33605496 DOI: 10.1111/cas.14858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
182 Yan HH, Jung KH, Lee JE, Son MK, Fang Z, Park JH, Kim SJ, Kim JY, Lim JH, Hong SS. ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis. Cancer Lett 2021;519:185-98. [PMID: 34311032 DOI: 10.1016/j.canlet.2021.07.036] [Reference Citation Analysis]
183 Suh HN, Jun S, Oh AY, Srivastava M, Lee S, Taniguchi CM, Zhang S, Lee WS, Chen J, Park BJ, Park JI. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Sci Rep 2016;6:38273. [PMID: 27922049 DOI: 10.1038/srep38273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
184 Yang J, Guo F, Yuan L, Lv G, Gong J, Chen J. Elevated expression of the V‐ATPase D2 subunit triggers increased energy metabolite levels in Kras G12D ‐driven cancer cells. J Cell Biochem 2019;120:11690-701. [DOI: 10.1002/jcb.28448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Balendran-Braun S, Kieler M, Liebmann-Reindl S, Unseld M, Bianconi D, W Prager G, Streubel B. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Cancer Manag Res 2021;13:6249-61. [PMID: 34393517 DOI: 10.2147/CMAR.S308029] [Reference Citation Analysis]
186 Sugimori M, Sugimori K, Tsuchiya H, Suzuki Y, Tsuyuki S, Kaneta Y, Hirotani A, Sanga K, Tozuka Y, Komiyama S, Sato T, Tezuka S, Goda Y, Irie K, Miwa H, Miura Y, Ishii T, Kaneko T, Nagahama M, Shibata W, Nozaki A, Maeda S. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci 2020;111:266-78. [PMID: 31746520 DOI: 10.1111/cas.14245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
187 Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. [New insights into the origin of pancreatic cancer. Role of atypical flat lesions in pancreatic carcinogenesis]. Pathologe. 2012;33 Suppl 2:189-193. [PMID: 23011021 DOI: 10.1007/s00292-012-1673-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
188 Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer. 2013;119:1669-1674. [PMID: 23335286 DOI: 10.1002/cncr.27955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 7.8] [Reference Citation Analysis]
189 Hata T, Suenaga M, Marchionni L, Macgregor-Das A, Yu J, Shindo K, Tamura K, Hruban RH, Goggins M. Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol. 2018;188:1723-1733. [PMID: 29684357 DOI: 10.1016/j.ajpath.2018.03.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
190 Ideno N, Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Tamura K, Aso T, Aishima S, Miyasaka Y, Ohuchida K, Ueda J, Takahata S, Oda Y, Mizumoto K, Tanaka M. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Pancreas 2015;44:311-20. [PMID: 25479586 DOI: 10.1097/MPA.0000000000000258] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
191 Yu J, Sadakari Y, Shindo K, Suenaga M, Brant A, Almario JAN, Borges M, Barkley T, Fesharakizadeh S, Ford M, Hruban RH, Shin EJ, Lennon AM, Canto MI, Goggins M. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66:1677-1687. [PMID: 27432539 DOI: 10.1136/gutjnl-2015-311166] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 14.7] [Reference Citation Analysis]
192 Makohon-Moore AP, Matsukuma K, Zhang M, Reiter JG, Gerold JM, Jiao Y, Sikkema L, Attiyeh MA, Yachida S, Sandone C, Hruban RH, Klimstra DS, Papadopoulos N, Nowak MA, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 2018;561:201-5. [PMID: 30177826 DOI: 10.1038/s41586-018-0481-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
193 Fennell M, Commisso C, Ramirez C, Garippa R, Bar-Sagi D. High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis. Assay Drug Dev Technol 2015;13:347-55. [PMID: 26267765 DOI: 10.1089/adt.2015.660] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
194 Li Y, Tang P, Cai S, Peng J, Hua G. Organoid based personalized medicine: from bench to bedside. Cell Regen 2020;9:21. [PMID: 33135109 DOI: 10.1186/s13619-020-00059-z] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
195 Ikuta K, Fukuda A, Ogawa S, Masuo K, Goto N, Hiramatsu Y, Tsuda M, Kimura Y, Matsumoto Y, Kimura Y, Maruno T, Kanda K, Nishi K, Takaori K, Uemoto S, Takaishi S, Chiba T, Nishi E, Seno H. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Gut 2019;68:882-92. [PMID: 29798841 DOI: 10.1136/gutjnl-2017-315425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
196 Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch. 2015;466:665-674. [PMID: 25796395 DOI: 10.1007/s00428-015-1751-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
197 Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers (Basel). 2018;10. [PMID: 29320420 DOI: 10.3390/cancers10010016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
198 Date K, Ohtsuka T, Fujimoto T, Tamura K, Kimura H, Matsunaga T, Mochidome N, Miyazaki T, Mori Y, Oda Y, Nakamura M, Tanaka M. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 2017;265:969-77. [DOI: 10.1097/sla.0000000000001755] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
199 di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-egly C, Lo-coco F, Ascenzi P, Nervi C. Retinoic acid receptors: From molecular mechanisms to cancer therapy. Molecular Aspects of Medicine 2015;41:1-115. [DOI: 10.1016/j.mam.2014.12.003] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 25.1] [Reference Citation Analysis]
200 Innamorati G, Wilkie TM, Kantheti HS, Valenti MT, Dalle Carbonare L, Giacomello L, Parenti M, Melisi D, Bassi C. The curious case of Gαs gain-of-function in neoplasia. BMC Cancer 2018;18:293. [PMID: 29544460 DOI: 10.1186/s12885-018-4133-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
201 Grizzi F, Fiorino S, Qehajaj D, Fornelli A, Russo C, de Biase D, Masetti M, Mastrangelo L, Zanello M, Lombardi R, Domanico A, Accogli E, Tura A, Mirandola L, Chiriva-Internati M, Bresalier RS, Jovine E, Leandri P, Di Tommaso L. Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study. J Transl Med 2019;17:61. [PMID: 30819202 DOI: 10.1186/s12967-019-1817-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
202 Fabbri C, Gibiino G, Fornelli A, Cennamo V, Grifoni D, Visani M, Acquaviva G, Fassan M, Fiorino S, Giovanelli S, Bassi M, Ghersi S, Tallini G, Jovine E, Gasbarrini A, de Biase D. Team work and cytopathology molecular diagnosis of solid pancreatic lesions. Dig Endosc. 2017;29:657-666. [PMID: 28190274 DOI: 10.1111/den.12845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
203 Hwang CI, Boj SF, Clevers H, Tuveson DA. Preclinical models of pancreatic ductal adenocarcinoma. J Pathol. 2016;238:197-204. [PMID: 26419819 DOI: 10.1002/path.4651] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
204 Satoh K. Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer.Diagnostics (Basel). 2021;11. [PMID: 33671729 DOI: 10.3390/diagnostics11020375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Durante S, Vecchiarelli S, Astolfi A, Grassi E, Casadei R, Santini D, Panzacchi R, Ricci C, Serravalle S, Tarantino G, Falconi M, Teti G, Indio V, Pession A, Minni F, Biasco G, Di Marco M. Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression. Oncotarget 2016;7:74797-806. [PMID: 27566563 DOI: 10.18632/oncotarget.11501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
206 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Ikeda M. New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. J Clin Med 2019;8:E1173. [PMID: 31387310 DOI: 10.3390/jcm8081173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
207 Chen C, Huang Y, Zhang C, Liu T, Zheng HE, Wan S, Sun S, Meng Q, Chen Y, Wei J. Circulating antibodies to p16 protein-derived peptides in breast cancer. Mol Clin Oncol 2015;3:591-4. [PMID: 26137272 DOI: 10.3892/mco.2015.485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
208 Bakke J, Wright WC, Zamora AE, Oladimeji P, Crawford JC, Brewer CT, Autry RJ, Evans WE, Thomas PG, Chen T. Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. BMC Cancer 2019;19:253. [PMID: 30898113 DOI: 10.1186/s12885-019-5455-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
209 Yang WW, Yang L, Lu HZ, Sun YK. Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature. World J Clin Cases 2021; 9(30): 9134-9143 [PMID: 34786397 DOI: 10.12998/wjcc.v9.i30.9134] [Reference Citation Analysis]
210 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
211 Bisht S, Feldmann G. Animal models for modeling pancreatic cancer and novel drug discovery. Expert Opinion on Drug Discovery 2018;14:127-42. [DOI: 10.1080/17460441.2019.1566319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
212 Liu Y, Wu W, Wang Y, Han S, Yuan Y, Huang J, Shuai X, Peng Z. Recent development of gene therapy for pancreatic cancer using non-viral nanovectors. Biomater Sci 2021. [PMID: 34378568 DOI: 10.1039/d1bm00748c] [Reference Citation Analysis]
213 Hareendran S, Yang X, Lou H, Xiao L, Loh YP. Carboxypeptidase E-∆N Promotes Proliferation and Invasion of Pancreatic Cancer Cells via Upregulation of CXCR2 Gene Expression. Int J Mol Sci 2019;20:E5725. [PMID: 31731578 DOI: 10.3390/ijms20225725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
214 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS. GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice. Proc Natl Acad Sci U S A 2017;114:E4020-9. [PMID: 28461470 DOI: 10.1073/pnas.1616060114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
216 Korsse SE, Peppelenbosch MP, Smits R, van Veelen W. GNAS is not involved in gastrointestinal tumour formation in Peutz-Jeghers syndrome. Fam Cancer 2013;12:581-2. [PMID: 23337932 DOI: 10.1007/s10689-013-9602-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
217 Esposito I, Häberle L, Yavas A, Kraft A, Gaida MM. [Intraductal neoplasms of the pancreas]. Pathologe 2021;42:472-83. [PMID: 34402978 DOI: 10.1007/s00292-021-00966-1] [Reference Citation Analysis]
218 Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34:3279-3292. [PMID: 23949878 DOI: 10.1007/s13277-013-1033-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
219 Lin J, Wu YJ, Liang X, Ji M, Ying HM, Wang XY, Sun X, Shao CH, Zhan LX, Zhang Y. Network-based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer. Mol Carcinog 2019;58:206-18. [PMID: 30294829 DOI: 10.1002/mc.22920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
220 Yang K, Li Y, Lian G, Lin H, Shang C, Zeng L, Chen S, Li J, Huang C, Huang K, Chen Y. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Int J Cancer 2018;142:2323-34. [PMID: 29315556 DOI: 10.1002/ijc.31248] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
221 Eibl G, Rozengurt E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol. 2019;54:50-62. [PMID: 29079305 DOI: 10.1016/j.semcancer.2017.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
222 Hayashi A, Hong J, Iacobuzio-Donahue CA. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 2021;18:469-81. [PMID: 34089011 DOI: 10.1038/s41575-021-00463-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
223 Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli ML, Meng X, LaFemina J, Whalen G, Belkin E, Zivny J, Wassef W, Woda BA, Hutchinson LM, Cosar EF. Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Oncotarget 2019;10:4026-37. [PMID: 31258847 DOI: 10.18632/oncotarget.26999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Deng L, Zhang H, Zhang Y, Luo S, Du Z, Lin Q, Zhang Z, Zhang L. An exosome-mimicking membrane hybrid nanoplatform for targeted treatment toward Kras-mutant pancreatic carcinoma. Biomater Sci 2021;9:5599-611. [PMID: 34250995 DOI: 10.1039/d1bm00446h] [Reference Citation Analysis]
225 Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach JP, Helm O, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzel P, Schneider G, Saur D, Schäfer H, Sebens S. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Oncoimmunology 2017;7:e1368603. [PMID: 29296518 DOI: 10.1080/2162402X.2017.1368603] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
226 Du W, Pasca di Magliano M, Zhang Y. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. Front Oncol 2021;11:682217. [PMID: 34290984 DOI: 10.3389/fonc.2021.682217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 Patra KC, Bardeesy N, Mizukami Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol. 2017;8:e86. [PMID: 28383565 DOI: 10.1038/ctg.2017.3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
228 Kren N, Michaud D, Bagchi S, Greene K, Pylayeva-Gupta Y. Rab27a plays a dual role in metastatic propensity of pancreatic cancer. Sci Rep 2020;10:7390. [PMID: 32355248 DOI: 10.1038/s41598-020-64248-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
229 Fassan M, Rusev B, Corbo V, Gasparini P, Luchini C, Vicentini C, Mafficini A, Paiella S, Salvia R, Cataldo I, Scarpa A, Huebner K. Fhit down-regulation is an early event in pancreatic carcinogenesis. Virchows Arch 2017;470:647-53. [PMID: 28289900 DOI: 10.1007/s00428-017-2105-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
230 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
231 Ling Q, Kalthoff H. Transportome Malfunctions and the Hallmarks of Pancreatic Cancer. Rev Physiol Biochem Pharmacol 2020. [PMID: 32770395 DOI: 10.1007/112_2020_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
232 Heinrich MA, Mostafa AMRH, Morton JP, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev 2021;174:265-93. [PMID: 33895214 DOI: 10.1016/j.addr.2021.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Choi KM, Cho E, Kim E, Shin JH, Kang M, Kim B, Han EH, Chung YH, Kim JY. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. Biochem Biophys Res Commun. 2018;507:311-318. [PMID: 30466782 DOI: 10.1016/j.bbrc.2018.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
234 Eibl G, Rozengurt E. Obesity and Pancreatic Cancer: Insight into Mechanisms. Cancers (Basel) 2021;13:5067. [PMID: 34680216 DOI: 10.3390/cancers13205067] [Reference Citation Analysis]
235 Tang Y, Cao G, Zhao G, Wang C, Qin Q. LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer. Invest New Drugs 2020;38:714-21. [DOI: 10.1007/s10637-019-00798-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
236 Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines. 2013;12:1211-1217. [PMID: 24090147 DOI: 10.1586/14760584.2013.836911] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 7.9] [Reference Citation Analysis]
237 Banerjee SK, Maity G, Haque I, Ghosh A, Sarkar S, Gupta V, Campbell DR, Von Hoff D, Banerjee S. Human pancreatic cancer progression: an anarchy among CCN-siblings. J Cell Commun Signal 2016;10:207-16. [PMID: 27541366 DOI: 10.1007/s12079-016-0343-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
238 Lomberk GA, Urrutia R. The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Surg Clin North Am. 2015;95:935-952. [PMID: 26315515 DOI: 10.1016/j.suc.2015.05.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
239 Dennaoui R, Shrestha H, Wagner KU. Models of pancreatic ductal adenocarcinoma. Cancer Metastasis Rev 2021;40:803-18. [PMID: 34491463 DOI: 10.1007/s10555-021-09989-9] [Reference Citation Analysis]
240 Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M. Proteasome activity is required for the initiation of precancerous pancreatic lesions. Sci Rep 2016;6:27044. [PMID: 27244456 DOI: 10.1038/srep27044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
241 Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA. Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 2018;38:e00427-17. [PMID: 29133460 DOI: 10.1128/MCB.00427-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
242 Tsuda M, Fukuda A, Roy N, Hiramatsu Y, Leonhardt L, Kakiuchi N, Hoyer K, Ogawa S, Goto N, Ikuta K, Kimura Y, Matsumoto Y, Takada Y, Yoshioka T, Maruno T, Yamaga Y, Kim GE, Akiyama H, Wright CV, Saur D, Takaori K, Uemoto S, Hebrok M, Chiba T, Seno H. The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. J Clin Invest. 2018;128:3475-3489. [PMID: 30010625 DOI: 10.1172/jci94287] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
243 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
244 Martinez-gonzalez LJ, Pascual Geler M, Robles Fernandez I, Cozar JM, Lorente JA, Alvarez Cubero MJ. Improving the genetic signature of prostate cancer, the somatic mutations. Urologic Oncology: Seminars and Original Investigations 2018;36:312.e17-23. [DOI: 10.1016/j.urolonc.2018.03.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
245 Reichert M, Blume K, Kleger A, Hartmann D, von Figura G. Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Stem Cells Int 2016;2016:9298535. [PMID: 26681957 DOI: 10.1155/2016/9298535] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
246 Wood LD, Hruban RH. Pathology and molecular genetics of pancreatic neoplasms. Cancer J. 2012;18:492-501. [PMID: 23187835 DOI: 10.1097/ppo.0b013e31827459b6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
247 Nagawkar SS, Abu-funni S, Simon E, Bick T, Prinz E, Sabo E, Ben-izhak O, Hershkovitz D. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. Pancreas 2016;45:876-81. [DOI: 10.1097/mpa.0000000000000562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
248 Macgregor-Das AM, Iacobuzio-Donahue CA. Molecular pathways in pancreatic carcinogenesis. J Surg Oncol. 2013;107:8-14. [PMID: 22806689 DOI: 10.1002/jso.23213] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
249 Rozengurt E, Eibl G. Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers (Basel) 2021;13:5126. [PMID: 34680275 DOI: 10.3390/cancers13205126] [Reference Citation Analysis]
250 Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91-100. [PMID: 24388967 DOI: 10.1016/j.tibs.2013.12.004] [Cited by in Crossref: 375] [Cited by in F6Publishing: 348] [Article Influence: 46.9] [Reference Citation Analysis]
251 Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, Rajan A, Giaccone G, Pastan I, Miettinen M, Hassan R. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 2015;6:11694-703. [PMID: 26028668 DOI: 10.18632/oncotarget.3429] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
252 Bailey-Lundberg JM, Guha S, Thosani N. From bench to bedside: Is it time to incorporate molecular testing for diagnostic and management algorithms for pancreatic cystic lesions? Gastrointest Endosc 2021;93:1034-7. [PMID: 33875142 DOI: 10.1016/j.gie.2021.01.041] [Reference Citation Analysis]
253 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1-10. [PMID: 29564165 DOI: 10.21037/jgo.2017.10.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
254 Alvarez Fallas ME, Pedraza-Arevalo S, Cujba AM, Manea T, Lambert C, Morrugares R, Sancho R. Stem/progenitor cells in normal physiology and disease of the pancreas. Mol Cell Endocrinol 2021;538:111459. [PMID: 34543699 DOI: 10.1016/j.mce.2021.111459] [Reference Citation Analysis]
255 Zhu B, Finkelstein SD, Feng G, Keswani RN, Lin X. Molecular analysis of mucinous nonneoplastic cyst of the pancreas. Hum Pathol 2016;55:159-63. [PMID: 27246174 DOI: 10.1016/j.humpath.2016.05.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
256 Brosens LA, Hackeng WM, Offerhaus GJ, Hruban RH, Wood LD. Pancreatic adenocarcinoma pathology: changing “landscape”. J Gastrointest Oncol. 2015;6:358-374. [PMID: 26261723 DOI: 10.3978/j.issn.2078-6891.2015.032] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
257 McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, Berger MF, Donoghue MTA, Yu KH, Varghese AM, Kelsen DP, Park W, Balachandran VP, Kingham TP, D'Angelica MI, Drebin JA, Jarnagin WR, Iacobuzio-Donahue CA, Allen PJ, O'Reilly EM. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer 2020;126:3939-49. [PMID: 32573775 DOI: 10.1002/cncr.33038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
258 Shen XH, Qi P, Du X. Long non-coding RNAs in cancer invasion and metastasis. Mod Pathol 2015;28:4-13. [PMID: 24925053 DOI: 10.1038/modpathol.2014.75] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
259 Fujiwara S, Saiki Y, Ishizawa K, Fukushige S, Yamanaka M, Sato M, Ishida M, Motoi F, Unno M, Horii A. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas. Cancer Med 2019;8:1671-8. [PMID: 30791220 DOI: 10.1002/cam4.2016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
260 Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon MC. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov 2016;6:256-69. [PMID: 26715642 DOI: 10.1158/2159-8290.CD-15-0822] [Cited by in Crossref: 104] [Cited by in F6Publishing: 78] [Article Influence: 14.9] [Reference Citation Analysis]
261 Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book 2015;:e222-7. [PMID: 25993177 DOI: 10.14694/EdBook_AM.2015.35.e222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
262 Goggins M. GLP-1 receptor agonist effects on normal and neoplastic pancreata. Diabetes. 2012;61:989-990. [PMID: 22517654 DOI: 10.2337/db12-0233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
263 Bartolacci C, Andreani C, El-Gammal Y, Scaglioni PP. Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy. Front Mol Biosci 2021;8:706650. [PMID: 34485382 DOI: 10.3389/fmolb.2021.706650] [Reference Citation Analysis]
264 Panzeri V, Manni I, Capone A, Naro C, Sacconi A, Di Agostino S, de Latouliere L, Montori A, Pilozzi E, Piaggio G, Capurso G, Sette C. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Mol Oncol 2021;15:579-95. [PMID: 33159833 DOI: 10.1002/1878-0261.12847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
265 Lee J, Snyder ER, Liu Y, Gu X, Wang J, Flowers BM, Kim YJ, Park S, Szot GL, Hruban RH, Longacre TA, Kim SK. Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. Nat Commun 2017;8:14686. [PMID: 28272465 DOI: 10.1038/ncomms14686] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
266 Ikezawa K, Hikita H, Shigekawa M, Iwahashi K, Eguchi H, Sakamori R, Tatsumi T, Takehara T. Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and Apoptosis. Cell Mol Gastroenterol Hepatol 2017;4:185-200.e1. [PMID: 28948203 DOI: 10.1016/j.jcmgh.2017.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
267 Shibayama Y, Takahashi K, Yamaguchi H, Yasuda J, Yamazaki D, Rahman A, Fujimori T, Fujisawa Y, Takai S, Furukawa T, Nakagawa T, Ohsaki H, Kobara H, Wong JH, Masaki T, Yuzawa Y, Kiyomoto H, Yachida S, Fujimoto A, Nishiyama A. Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Commun Biol 2020;3:724. [PMID: 33247206 DOI: 10.1038/s42003-020-01434-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes.Cancer J. 2012;18:485-491. [PMID: 23187834 DOI: 10.1097/PPO.0b013e318278c4a6] [Cited by in Crossref: 61] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
269 Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci. 2015;60:1256-1264. [PMID: 25487193 DOI: 10.1007/s10620-014-3477-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
270 Taylor-Weiner A, Stewart C, Giordano T, Miller M, Rosenberg M, Macbeth A, Lennon N, Rheinbay E, Landau DA, Wu CJ, Getz G. DeTiN: overcoming tumor-in-normal contamination. Nat Methods 2018;15:531-4. [PMID: 29941871 DOI: 10.1038/s41592-018-0036-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
271 Miglietta G, Cogoi S, Marinello J, Capranico G, Tikhomirov AS, Shchekotikhin A, Xodo LE. RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation. J Med Chem 2017;60:9448-61. [PMID: 29140695 DOI: 10.1021/acs.jmedchem.7b00622] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
272 Ye X, Wei X, Liao J, Chen P, Li X, Chen Y, Yang Y, Zhao Q, Sun H, Pan L, Chen G, He X, Lyu J, Fang H. 4-Hydroxyphenylpyruvate Dioxygenase-Like Protein Promotes Pancreatic Cancer Cell Progression and Is Associated With Glutamine-Mediated Redox Balance. Front Oncol 2020;10:617190. [PMID: 33537239 DOI: 10.3389/fonc.2020.617190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
273 Xie VK, He J, Xie K. Protein arginine methylation promotes therapeutic resistance in human pancreatic cancer. Cytokine Growth Factor Rev 2020;55:58-69. [PMID: 32739260 DOI: 10.1016/j.cytogfr.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
274 Xu R, Yang J, Ren B, Wang H, Yang G, Chen Y, You L, Zhao Y. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Front Oncol 2020;10:572722. [PMID: 33117704 DOI: 10.3389/fonc.2020.572722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
275 Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202-213. [PMID: 31158393 DOI: 10.1016/j.pharmthera.2019.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
276 Hong SM, Vincent A, Kanda M, Leclerc J, Omura N, Borges M, Klein AP, Canto MI, Hruban RH, Goggins M. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res 2012;18:4303-12. [PMID: 22723370 DOI: 10.1158/1078-0432.CCR-12-1075] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
277 Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology. 2016;151:526-539. [PMID: 27215660 DOI: 10.1053/j.gastro.2016.05.006] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 17.7] [Reference Citation Analysis]
278 Das KK, Brown JW, Fernandez Del-Castillo C, Huynh T, Mills JC, Matsuda Y, Das KM, Mino-Kenudson M. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy. Hum Pathol 2021;111:36-44. [PMID: 33524436 DOI: 10.1016/j.humpath.2021.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
279 Aravindan S, Delma CR, Thirugnanasambandan SS, Herman TS, Aravindan N. Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae. PLoS One 2013;8:e61977. [PMID: 23613993 DOI: 10.1371/journal.pone.0061977] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
280 Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (Basel) 2019;11:E1659. [PMID: 31717773 DOI: 10.3390/cancers11111659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
281 Ayres Pereira M, Chio IIC. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel) 2019;11:E6. [PMID: 31861620 DOI: 10.3390/genes11010006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
282 Xodo LE, Cogoi S, Rapozzi V. Photosensitizers binding to nucleic acids as anticancer agents. Future Medicinal Chemistry 2016;8:179-94. [DOI: 10.4155/fmc.15.180] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
283 Ma C, Gocke CD, Hruban RH, Belchis DA. Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. Hum Pathol 2016;48:117-21. [PMID: 26626780 DOI: 10.1016/j.humpath.2015.09.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
284 Dumartin L, Alrawashdeh W, Trabulo SM, Radon TP, Steiger K, Feakins RM, di Magliano MP, Heeschen C, Esposito I, Lemoine NR, Crnogorac-Jurcevic T. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene 2017;36:3094-103. [PMID: 27941872 DOI: 10.1038/onc.2016.459] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
285 Liu XY, Guo CH, Xi ZY, Xu XQ, Zhao QY, Li LS, Wang Y. Histone methylation in pancreatic cancer and its clinical implications. World J Gastroenterol 2021; 27(36): 6004-6024 [PMID: 34629816 DOI: 10.3748/wjg.v27.i36.6004] [Reference Citation Analysis]
286 Sipos B, Sperveslage J. [Will molecular diagnostics become established in pancreatic pathology?]. Pathologe 2013;34 Suppl 2:214-20. [PMID: 24196616 DOI: 10.1007/s00292-013-1865-z] [Reference Citation Analysis]
287 Vorvis C, Koutsioumpa M, Iliopoulos D. Developments in miRNA gene signaling pathways in pancreatic cancer. Future Oncol. 2016;12:1135-1150. [PMID: 26984178 DOI: 10.2217/fon-2015-0050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
288 Sano M, Driscoll DR, De Jesus-Monge WE, Klimstra DS, Lewis BC. Activated wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. Gastroenterology 2014;146:257-67. [PMID: 24067880 DOI: 10.1053/j.gastro.2013.09.044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
289 Kim MJ, Chang H, Nam G, Ko Y, Kim SH, Roberts TM, Ryu JH. RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics 2021;13:1638. [PMID: 34683931 DOI: 10.3390/pharmaceutics13101638] [Reference Citation Analysis]
290 Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology. 2018;18:928-934. [PMID: 30143405 DOI: 10.1016/j.pan.2018.07.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
291 Cogoi S, Xodo LE. G4 DNA in ras genes and its potential in cancer therapy. Biochim Biophys Acta 2016;1859:663-74. [PMID: 26855080 DOI: 10.1016/j.bbagrm.2016.02.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
292 Menini S, Iacobini C, Vitale M, Pesce C, Pugliese G. Diabetes and Pancreatic Cancer-A Dangerous Liaison Relying on Carbonyl Stress. Cancers (Basel). 2021;13. [PMID: 33467038 DOI: 10.3390/cancers13020313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
293 Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013;32:5253-60. [PMID: 23416985 DOI: 10.1038/onc.2013.29] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 13.3] [Reference Citation Analysis]
294 Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
295 Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, Galbán CJ, Galbán S, di Magliano MP. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 2012;7:e49707. [PMID: 23226501 DOI: 10.1371/journal.pone.0049707] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 11.1] [Reference Citation Analysis]
296 Singh H, Mcgrath K, Singhi AD. Novel Biomarkers for Pancreatic Cysts. Dig Dis Sci 2017;62:1796-807. [DOI: 10.1007/s10620-017-4491-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
297 Neuhöfer P, Roake CM, Kim SJ, Lu RJ, West RB, Charville GW, Artandi SE. Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis. Nature 2021;597:715-9. [PMID: 34526722 DOI: 10.1038/s41586-021-03916-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
298 Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP 4th, Pan FC, Akiyama H, Wright CV, Jensen K, Hebrok M, Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:737-750. [PMID: 23201164 DOI: 10.1016/j.ccr.2012.10.025] [Cited by in Crossref: 388] [Cited by in F6Publishing: 357] [Article Influence: 38.8] [Reference Citation Analysis]
299 Xiao S, Ye Z. Pancreatic cystic tumors: an update. Journal of Pancreatology 2018;1:2-18. [DOI: 10.1097/jp9.0000000000000003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
300 Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol 2020;17:203-22. [PMID: 32099092 DOI: 10.1038/s41575-019-0255-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
301 Attiyeh M, Zhang L, Iacobuzio-Donahue C, Allen P, Imam R, Basturk O, Klimstra DS, Sigel CS. Simple mucinous cysts of the pancreas have heterogeneous somatic mutations. Hum Pathol 2020;101:1-9. [PMID: 32380013 DOI: 10.1016/j.humpath.2020.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Kim JY, Hong S. Precursor Lesions of Pancreatic Cancer. Oncol Res Treat 2018;41:603-10. [DOI: 10.1159/000493554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
303 Muyinda IJ, Park JG, Jang EJ, Yoo BC. KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. Int J Mol Sci 2021;22:5070. [PMID: 34064761 DOI: 10.3390/ijms22105070] [Reference Citation Analysis]
304 Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P. Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.J Clin Med. 2020;9. [PMID: 33371431 DOI: 10.3390/jcm9124128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
305 Fendrich V, Jendryschek F, Beeck S, Albers M, Lauth M, Esni F, Heeger K, Dengler J, Slater EP, Holler JPN, Baier A, Bartsch DK, Waldmann J. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury. Oncogene 2018;37:1845-56. [PMID: 29367759 DOI: 10.1038/s41388-017-0100-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
306 Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer 2018;18:767-77. [DOI: 10.1038/s41568-018-0076-6] [Cited by in Crossref: 119] [Cited by in F6Publishing: 105] [Article Influence: 29.8] [Reference Citation Analysis]
307 Matsuda Y, Tanaka M, Sawabe M, Mori S, Muramatsu M, Mieno MN, Ishiwata T, Arai T. The stem cell-specific intermediate filament nestin missense variation p.A1199P is associated with pancreatic cancer. Oncol Lett 2019;17:4647-54. [PMID: 30988821 DOI: 10.3892/ol.2019.10106] [Reference Citation Analysis]
308 McCarty TR, Paleti S, Rustagi T. Molecular analysis of EUS-acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: a systematic review and meta-analysis.Gastrointest Endosc. 2021;93:1019-1033.e5. [PMID: 33359054 DOI: 10.1016/j.gie.2020.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
309 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
310 Lin E, Rivera-báez L, Fouladdel S, Yoon HJ, Guthrie S, Wieger J, Deol Y, Keller E, Sahai V, Simeone DM, Burness ML, Azizi E, Wicha MS, Nagrath S. High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. Cell Systems 2017;5:295-304.e4. [DOI: 10.1016/j.cels.2017.08.012] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
311 Guo Y, Xiao Y, Guo H, Zhu H, Chen D, Wang J, Deng J, Lan J, Liu X, Zhang Q, Bai Y. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Aging (Albany NY) 2021;13:18545-63. [PMID: 34320467 DOI: 10.18632/aging.203301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
312 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
313 Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111:817-822. [PMID: 24755884 DOI: 10.1038/bjc.2014.215] [Cited by in Crossref: 304] [Cited by in F6Publishing: 295] [Article Influence: 38.0] [Reference Citation Analysis]
314 Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7:78827-78840. [PMID: 27705932 DOI: 10.18632/oncotarget.12386] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
315 Du Y, Shang BY, Sheng WJ, Zhang SH, Li Y, Miao QF, Zhen YS. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Oncotarget 2016;7:58418-34. [PMID: 27517152 DOI: 10.18632/oncotarget.11170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
316 Ako S, Nouso K, Kinugasa H, Dohi C, Matushita H, Mizukawa S, Muro S, Akimoto Y, Uchida D, Tomoda T, Matsumoto K, Horiguchi S, Tsutsumi K, Kato H, Okada H. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology 2017;17:285-90. [PMID: 28139399 DOI: 10.1016/j.pan.2016.12.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
317 Jin Y, Guan S, Liu L, Sun S, Lee KH, Wei J. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asia Pac J Clin Oncol. 2015;11:e37-e41. [PMID: 24811068 DOI: 10.1111/ajco.12198] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
318 Rodríguez Gil Y, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. Int J Mol Sci 2021;22:2077. [PMID: 33669845 DOI: 10.3390/ijms22042077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
319 Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229669 DOI: 10.1101/cshperspect.a031435] [Cited by in Crossref: 201] [Cited by in F6Publishing: 198] [Article Influence: 50.3] [Reference Citation Analysis]
320 Singh K, Pruski M, Bland R, Younes M, Guha S, Thosani N, Maitra A, Cash BD, McAllister F, Logsdon CD, Chang JT, Bailey-Lundberg JM. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Lab Invest 2021;101:177-92. [PMID: 33009500 DOI: 10.1038/s41374-020-00490-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
321 Okada T, Iwano H, Ono Y, Karasaki H, Sato T, Yamada M, Omori Y, Sato H, Hayashi A, Kawabata H, Goto T, Sasajima J, Takauji S, Nagashima K, Mizukami Y, Okumura T. Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. Endosc Int Open 2018;6:E1454-61. [PMID: 30539069 DOI: 10.1055/a-0721-1747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
322 Qiu J, Xu J, Zhang K, Gu W, Nie L, Wang G, Luo Y. Refining Cancer Management Using Integrated Liquid Biopsy. Theranostics 2020;10:2374-84. [PMID: 32089746 DOI: 10.7150/thno.40677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
323 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 24.7] [Reference Citation Analysis]
324 Urata T, Naito Y, Nagamine M, Izumi Y, Tonaki G, Iwasaki H, Sasaki A, Yamasaki A, Minami N, Yoshioka R, Kitada H, Takekuma Y, Yokomizo H, Fukuda S, Yamaguchi H, Kuboki Y, Furukawa T, Hifumi M. Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation. Clin J Gastroenterol 2012;5:413-20. [PMID: 26181322 DOI: 10.1007/s12328-012-0342-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
325 Yokode M, Akita M, Fujikura K, Kim MJ, Morinaga Y, Yoshikawa S, Terada T, Matsukiyo H, Tajiri T, Abe-Suzuki S. High-grade PanIN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer. Histopathology. 2018;73:247-258. [PMID: 29660164 DOI: 10.1111/his.13629] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
326 Kinugawa Y, Uehara T, Sano K, Matsuda K, Maruyama Y, Kobayashi Y, Nakajima T, Hamano H, Kawa S, Higuchi K, Hosaka N, Shiozawa S, Ishigame H, Ota H. Methylation of Tumor Suppressor Genes in Autoimmune Pancreatitis. Pancreas. 2017;46:614-618. [PMID: 28196014 DOI: 10.1097/mpa.0000000000000804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
327 Kovalenko I, Glasauer A, Schöckel L, Sauter DR, Ehrmann A, Sohler F, Hägebarth A, Novak I, Christian S. Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines. PLoS One 2016;11:e0160658. [PMID: 27494181 DOI: 10.1371/journal.pone.0160658] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
328 Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol. 2013;4:407. [PMID: 24478710 DOI: 10.3389/fphys.2013.00407] [Cited by in Crossref: 38] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
329 Kato S, Honda K. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers (Basel) 2020;12:E1965. [PMID: 32707720 DOI: 10.3390/cancers12071965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
330 Mathew E, Collins MA, Fernandez-Barrena MG, Holtz AM, Yan W, Hogan JO, Tata Z, Allen BL, Fernandez-Zapico ME, di Magliano MP. The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. J Biol Chem 2014;289:27727-43. [PMID: 25104358 DOI: 10.1074/jbc.M114.556563] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
331 Seimiya T, Otsuka M, Iwata T, Tanaka E, Suzuki T, Sekiba K, Yamagami M, Ishibashi R, Koike K. Inflammation and de-differentiation in pancreatic carcinogenesis. World J Clin Cases 2018; 6(15): 882-891 [PMID: 30568942 DOI: 10.12998/wjcc.v6.i15.882] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
332 Kane LE, Mellotte GS, Conlon KC, Ryan BM, Maher SG. Multi-Omic Biomarkers as Potential Tools for the Characterisation of Pancreatic Cystic Lesions and Cancer: Innovative Patient Data Integration. Cancers (Basel) 2021;13:769. [PMID: 33673153 DOI: 10.3390/cancers13040769] [Reference Citation Analysis]
333 Carozzo A, Yaneff A, Gómez N, Di Siervi N, Sahores A, Diez F, Attorresi AI, Rodríguez-González Á, Monczor F, Fernández N, Abba M, Shayo C, Davio C. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux. Mol Pharmacol 2019;96:13-25. [PMID: 31043460 DOI: 10.1124/mol.118.115444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
334 Yang HJ, Song BS, Sim BW, Jung Y, Chae U, Lee DG, Cha JJ, Baek SJ, Lim KS, Choi WS, Lee HY, Son HC, Park SH, Jeong KJ, Kang P, Baek SH, Koo BS, Kim HN, Jin YB, Park YH, Choo YK, Kim SU. Establishment and Characterization of Immortalized Miniature Pig Pancreatic Cell Lines Expressing Oncogenic K-RasG12D. Int J Mol Sci 2020;21:E8820. [PMID: 33233448 DOI: 10.3390/ijms21228820] [Reference Citation Analysis]
335 Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC. Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. Pancreas 2018;47:924-36. [PMID: 30113427 DOI: 10.1097/MPA.0000000000001136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
336 Ning G, Li Y, Chen W, Tang W, Shou D, Luo Q, Chen H, Zhou Y. CpG Island Methylator Phenotype Modulates the Immune Response of the Tumor Microenvironment and Influences the Prognosis of Pancreatic Cancer Patients. J Oncol 2021;2021:2715694. [PMID: 34876903 DOI: 10.1155/2021/2715694] [Reference Citation Analysis]
337 Gu D, Schlotman KE, Xie J. Deciphering the role of hedgehog signaling in pancreatic cancer. J Biomed Res. 2016;30:353-360. [PMID: 27346466 DOI: 10.7555/jbr.30.20150107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
338 Utomo WK, Braat H, Bruno MJ, van Eijck CHJ, Koerkamp BG, Krak NC, van de Vreede A, Fuhler GM, Peppelenbosch MP, Biermann K. Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms. Medicine (Baltimore) 2015;94:e988. [PMID: 26091476 DOI: 10.1097/MD.0000000000000988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
339 Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Carcinogenesis 2014;35:2404-14. [PMID: 24947179 DOI: 10.1093/carcin/bgu136] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 7.5] [Reference Citation Analysis]
340 Hosoda W, Chianchiano P, Griffin JF, Pittman ME, Brosens LA, Noë M, Yu J, Shindo K, Suenaga M, Rezaee N, Yonescu R, Ning Y, Albores-Saavedra J, Yoshizawa N, Harada K, Yoshizawa A, Hanada K, Yonehara S, Shimizu M, Uehara T, Samra JS, Gill AJ, Wolfgang CL, Goggins MG, Hruban RH, Wood LD. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 2017;242:16-23. [PMID: 28188630 DOI: 10.1002/path.4884] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 13.2] [Reference Citation Analysis]
341 Fullerton PT Jr, Creighton CJ, Matzuk MM. Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling. Mol Endocrinol 2015;29:1440-53. [PMID: 26284758 DOI: 10.1210/me.2015-1102] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
342 Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 2017;5. [PMID: 29156578 DOI: 10.3390/biomedicines5040065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
343 Liao X, Han C, Wang X, Huang K, Yu T, Yang C, Huang R, Liu Z, Han Q, Peng T. Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy. Cancer Manag Res 2018;10:3255-71. [PMID: 30233242 DOI: 10.2147/CMAR.S171293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
344 Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553-565. [PMID: 27444064 DOI: 10.1038/nrc.2016.66] [Cited by in Crossref: 183] [Cited by in F6Publishing: 180] [Article Influence: 30.5] [Reference Citation Analysis]
345 Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer 2021. [PMID: 34789870 DOI: 10.1038/s41568-021-00418-1] [Reference Citation Analysis]
346 Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:318-330. [PMID: 22975375 DOI: 10.1016/j.ccr.2012.08.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 230] [Article Influence: 24.7] [Reference Citation Analysis]
347 Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, Furukawa E, Kato M, Hayashi H, Kohno T, Ueno H, Shimada K, Okusaka T, Nakagama H, Shibata T, Yachida S. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015;5:18425. [PMID: 26669280 DOI: 10.1038/srep18425] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 16.3] [Reference Citation Analysis]
348 Park JT, Johnson N, Liu S, Levesque M, Wang YJ, Ho H, Huso D, Maitra A, Parsons MJ, Prescott JD. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene. 2015;34:2801-2806. [PMID: 25065594 DOI: 10.1038/onc.2014.223] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
349 Kha ML, Hesse L, Deisinger F, Sipos B, Röcken C, Arlt A, Sebens S, Helm O, Schäfer H. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2. Oncogene 2019;38:1461-76. [PMID: 30302023 DOI: 10.1038/s41388-018-0518-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
350 Shibata H, Komura S, Yamada Y, Sankoda N, Tanaka A, Ukai T, Kabata M, Sakurai S, Kuze B, Woltjen K. In vivo reprogramming drives Kras-induced cancer development. Nat Commun. 2018;9:2081. [PMID: 29802314 DOI: 10.1038/s41467-018-04449-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
351 Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol. 2013;27:299-322. [PMID: 23809247 DOI: 10.1016/j.bpg.2013.04.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
352 Fu Z, Liang X, Shi L, Tang L, Chen D, Liu A, Shao C. SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway. Cell Death Discov 2021;7:390. [PMID: 34907162 DOI: 10.1038/s41420-021-00779-4] [Reference Citation Analysis]
353 Jun SY, Son D, Kim MJ, Kim SJ, An S, Park YS, Park SR, Choi KD, Jung HY, Kim SC, Yook JH, Kim BS, Hong SM. Heterotopic Pancreas of the Gastrointestinal Tract and Associated Precursor and Cancerous Lesions: Systematic Pathologic Studies of 165 Cases. Am J Surg Pathol 2017;41:833-48. [PMID: 28368927 DOI: 10.1097/PAS.0000000000000850] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
354 Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Target Oncol 2017;12:97-109. [PMID: 27975152 DOI: 10.1007/s11523-016-0469-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
355 Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015;33:1779-1786. [PMID: 25918299 DOI: 10.1200/jco.2014.59.7625] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
356 Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: Facts, challenges and future developments. World J Gastroenterol 2014; 20(38): 13833-13841 [PMID: 25320520 DOI: 10.3748/wjg.v20.i38.13833] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
357 Ding L, Billadeau DD. Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer. Expert Opin Ther Targets 2020;24:417-26. [PMID: 32178549 DOI: 10.1080/14728222.2020.1743681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
358 Terasawa H, Kinugasa H, Ako S, Hirai M, Matsushita H, Uchida D, Tomoda T, Matsumoto K, Horiguchi S, Kato H, Nouso K, Okada H. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2019;20:1348-1353. [PMID: 31328611 DOI: 10.1080/15384047.2019.1638685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
359 Sandforth L, Ammar N, Dinges LA, Röcken C, Arlt A, Sebens S, Schäfer H. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †. Cancers (Basel) 2020;12:E581. [PMID: 32138176 DOI: 10.3390/cancers12030581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
360 Suenaga M, Yu J, Shindo K, Tamura K, Almario JA, Zaykoski C, Witmer PD, Fesharakizadeh S, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clin Cancer Res. 2018;24:2963-2974. [PMID: 29301828 DOI: 10.1158/1078-0432.ccr-17-2463] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
361 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
362 Chu NJ, Anders RA, Fertig EJ, Cao M, Hopkins AC, Keenan BP, Popovic A, Armstrong TD, Jaffee EM, Zimmerman JW. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. Cancer Prev Res (Phila) 2020;13:569-82. [PMID: 32409593 DOI: 10.1158/1940-6207.CAPR-20-0053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Kato K, Kamada H, Fujimori T, Aritomo Y, Ono M, Masaki T. Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration. Gastroenterol Res Pract 2012;2012:243524. [PMID: 23197977 DOI: 10.1155/2012/243524] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
364 Smit MA, Jaffee EM, Lutz ER. Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) 2014;7:1072-80. [PMID: 25245763 DOI: 10.1158/1940-6207.CAPR-14-0178] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
365 Huang L, Desai R, Conrad DN, Leite NC, Akshinthala D, Lim CM, Gonzalez R, Muthuswamy LB, Gartner Z, Muthuswamy SK. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell 2021;28:1090-1104.e6. [PMID: 33915081 DOI: 10.1016/j.stem.2021.03.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
366 Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, Boldorini R. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. Pathology. 2017;49:379-386. [PMID: 28450086 DOI: 10.1016/j.pathol.2016.12.348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
367 Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016;10:481-493. [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
368 Haghighi M, Packey C, Gonda TA. Endoscopic Ultrasonography with Fine-needle Aspiration: New Techniques for Interpretation of Endoscopic Ultrasonography Cytology and Histology Specimens. Gastrointest Endosc Clin N Am 2017;27:601-14. [PMID: 28918801 DOI: 10.1016/j.giec.2017.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
369 Dawson DW, Hertzer K, Moro A, Donald G, Chang HH, Go VL, Pandol SJ, Lugea A, Gukovskaya AS, Li G, Hines OJ, Rozengurt E, Eibl G. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila). 2013;6:1064-1073. [PMID: 23943783 DOI: 10.1158/1940-6207.capr-13-0065] [Cited by in Crossref: 88] [Cited by in F6Publishing: 61] [Article Influence: 9.8] [Reference Citation Analysis]
370 Gotoh Y, Ohtsuka T, Nakamura S, Shindo K, Ohuchida K, Miyasaka Y, Mori Y, Mochidome N, Oda Y, Nakamura M. Genetic assessment of recurrent pancreatic high-risk lesions in the remnant pancreas: Metachronous multifocal lesion or local recurrence? Surgery 2019;165:767-74. [PMID: 30497813 DOI: 10.1016/j.surg.2018.10.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
371 Kawalerski RR, Leach SD, Escobar-Hoyos LF. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Oncotarget 2021;12:525-33. [PMID: 33796221 DOI: 10.18632/oncotarget.27901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]